Plant-Derived Antimicrobial Peptides: Structure, Families, and Therapeutic Potential Against Infections | Research

The takeaway

This review surveys the major families of plant antimicrobial peptides — including defensins, thionins, and cyclotides — examining their structures, mechanisms of action, and potential as therapeutic agents against bacterial and fungal diseases.

2-9 kDa defense molecules
Plant antimicrobial peptides are small, positively charged molecules that have evolved over hundreds of millions of years to combat diverse pathogens through multiple mechanisms of action.

What the researchers found

The review identifies several key families of plant antimicrobial peptides:

- Plant defensins — small cysteine-rich peptides with broad-spectrum antimicrobial activity

- Thionins — toxic peptides that disrupt pathogen cell membranes

- Cyclotides — exceptionally stable cyclic peptides with a wide range of biological activities

Transgenic overexpression of AMP genes in plants increases pathogen resistance, while pathogen mutants susceptible to these peptides show decreased virulence — confirming the peptides' direct role in defense. The review emphasizes that plant AMPs exhibit activity against diverse pathogens and could serve as templates for new antimicrobial drugs for human use.

Why it matters

With antibiotic resistance growing worldwide, plant-derived antimicrobial peptides represent an underexplored reservoir of potential new therapeutics. Plants have evolved these defense molecules over hundreds of millions of years of pathogen exposure, resulting in highly effective and diverse antimicrobial strategies. Understanding these peptides could lead to novel drugs that work through mechanisms different from conventional antibiotics, potentially bypassing existing resistance.

How the study worked

This is a comprehensive review article surveying the published literature on plant antimicrobial peptides. The authors compiled information on AMP family classifications, three-dimensional structures, mechanisms of antimicrobial action, factors influencing activity, and evidence for therapeutic potential in pharmaceutical and medical applications.

What this study cannot tell us

As a review article, this paper synthesizes existing research rather than presenting new experimental data. The therapeutic potential discussed is largely theoretical — most plant AMPs have not progressed to clinical trials in humans. Challenges including production scalability, potential toxicity to human cells, and pharmacokinetic properties (stability, bioavailability) are significant hurdles that are not fully addressed. The review covers a very broad topic, which may limit depth on any individual peptide family.

How to read the evidence

This is a narrative review published in a medicinal chemistry journal, providing a comprehensive overview of the field. It synthesizes preclinical and mechanistic evidence but does not include meta-analysis or clinical outcome data, placing it at a moderate evidence level for understanding the therapeutic landscape.

When this study was published

Published in 2025, this is a very current review capturing the latest understanding of plant antimicrobial peptides and their therapeutic potential in the context of the ongoing antibiotic resistance crisis.

The bigger picture

Antimicrobial peptides are found across all kingdoms of life — humans, animals, and plants all produce them. While human and animal AMPs (like defensins and cathelicidins) have received more pharmaceutical attention, plant AMPs offer unique structural features. Cyclotides, for example, have exceptional stability due to their circular backbone, making them attractive drug candidates. The convergent evolution of similar peptide families across kingdoms suggests these are highly optimized antimicrobial solutions that could inspire the next generation of anti-infective drugs.

Questions still open

Which plant antimicrobial peptide families are most promising for development into human therapeutics?
Can cyclotides' exceptional stability be harnessed to create oral antimicrobial peptide drugs that survive digestion?
How do the antimicrobial mechanisms of plant peptides compare to those of human defensins, and could they be combined for synergistic effects?

Common questions

What are plant antimicrobial peptides and how do they fight infections?

Plants produce small proteins called antimicrobial peptides (AMPs) as part of their immune defense. These peptides typically carry a positive charge that attracts them to negatively charged bacterial or fungal cell membranes, which they then disrupt — essentially poking holes in the pathogen's outer wall. Different families (defensins, thionins, cyclotides) use slightly different strategies, but all are effective against a broad range of microbes.

Could plant peptides replace antibiotics?

They could supplement or partially replace antibiotics for certain infections. Plant AMPs attack pathogens through mechanisms different from conventional antibiotics, making cross-resistance unlikely. Some, like cyclotides, are remarkably stable and could potentially be developed into drugs. However, significant research is still needed to address manufacturing, safety, and delivery challenges before they reach clinical use.

Read the original research

Antimicrobial Plant Peptides: Structure, Classification, Mechanism and Therapeutic Potential.

Current topics in medicinal chemistry, 25(27), 3103-3156

View on PubMed ↗Publisher’s paper ↗

Citation

Khan, Shaina Shahab; Luqman, Suaib. (2025). Antimicrobial Plant Peptides: Structure, Classification, Mechanism and Therapeutic Potential.. Current topics in medicinal chemistry, 25(27), 3103-3156. https://doi.org/10.2174/0115680266345963250121112522